Crinetics Pharmaceuticals, Inc. (CRNX)
After hours:
| Previous close | 49.42 |
| Open | 49.43 |
| Bid | 47.88 x 100 |
| Ask | 48.03 x 200 |
| Day's range | 47.52 - 50.37 |
| 52-week range | 15.76 - 51.29 |
| Volume | |
| Avg. volume | 831,773 |
| Market cap | 3.892B |
| Beta (5Y monthly) | 0.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.69 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 61.69 |
GlobeNewswireCrinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 176,000 shares of its common stock to fifteen new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m
GuruFocus.comCrinetics Pharmaceuticals Inc (CRNX) Reports Q1 2024 Financial Results
Despite Progress in Clinical Trials, Financial Strains Continue as Losses Widen
ZacksCrinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
